Related Experiment Videos
Ganglioside content and composition in human gliomas
1Institute of Neurosurgery, School of Medicine, University of Milano, Italy.
Acta Neurochirurgica. Supplementum
|January 1, 1988
Summary
Ganglioside content decreases with glioma malignancy, showing increased GD3 levels. This specific GD3 increase in gliomas suggests potential for targeted antibody development for tumor grading and localization.
Area of Science:
- Neuroscience
- Biochemistry
- Oncology
Background:
- Ganglioside alterations are common in tumors, with meningiomas showing increased monosialylgangliosides.
- Previous research indicated lipid alterations in meningiomas.
Purpose of the Study:
- To analyze ganglioside distribution and content in various gliomas.
- To investigate the potential of GD3 as a glioma-specific biomarker.
- To develop anti-GD3 monoclonal antibodies for immunohistochemical applications.
Main Methods:
- Analysis of ganglioside content and distribution in different glioma grades.
- Quantification of GD3 as a percentage of total ganglioside sialic acid.
- Production of monoclonal antibodies using purified GD3.
Main Results:
- Ganglioside content is inversely proportional to glioma tissue malignancy.
- Gliomas exhibit a lack of polysialylgangliosides with a significant increase in GD3 content.
- GD3 levels rise from 15% in astrocytomas grade I to 60% in grade IV gliomas.
- The observed GD3 increase appears specific to gliomas.
Conclusions:
- Ganglioside profiles differ significantly across glioma grades, correlating with malignancy.
- GD3 is a potential glioma-specific marker, increasing with tumor grade.
- Further research is needed to optimize anti-GD3 antibody production for clinical use in tumor localization and grading.